Arvinas ARVN 深 沪
等待开盘 09-05 09:30:00 美东时间
7.61
-0.290
-3.67%
华盛通- 最 高7.87
- 今 开7.87
- 成交量 119.96万股
- 最 低 7.47
- 昨 收 7.90
- 总市值 5.55亿
- 52周最高 29.6106
- 市盈率 静 --
- 换手率 1.64%
- 52周最低 5.90
- 委 比 69.54%
- 总股本 7299.14万
- 历史最高 108.465
- 量 比 1.00
- 振 幅 5.06%
- 历史最低 5.90
- 每 手 1
- 风险率 8.98%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Arvinas to Participate in Upcoming Investor Conferences
Arvinas, a clinical-stage biotech company, announced its participation in two investor conferences: the Wells Fargo Healthcare Conference on September 4 and the Cantor Global Healthcare Conference on September 5. Live audio webcasts of the presentations will be available on the Company’s website and via provided links. Arvinas, known for its PROTAC protein degrader platform, is developing therapies targeting disease-causing proteins, including tr...
08-29 11:00
Pfizer and Arvinas' breast cancer therapy to be reviewed by FDA
Arvinas (NASDAQ:ARVN), with its partner Pfizer (PFE), said that the U.S. FDA will review the marketing application for vepdegestrant, to treat patients with advanced or metastatic breast cancer who ha...
08-09 04:29
Arvinas and Pfizer’s FDA Nod for Cancer Drug
An update from Arvinas Holding Company ( ($ARVN) ) is now available. On August ...
08-09 04:29
Guggenheim Maintains Buy on Arvinas, Lowers Price Target to $15
Guggenheim analyst Michael Schmidt maintains Arvinas (NASDAQ:ARVN) with a Buy and lowers the price target from $16 to $15.
08-07 22:14
Arvinas shares are trading lower after the company reported mixed Q2 financial results.
Arvinas shares are trading lower after the company reported mixed Q2 financial ...
08-07 00:48
Earnings Scheduled For August 6, 2025
Companies Reporting Before The Bell • Lineage (NASDAQ:LINE) is likely to report...
08-06 16:33
Arvinas to Report Second Quarter 2025 Financial Results on August 6, 2025
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company focused on targeted protein degradation, announced that its management will discuss the second-quarter 2025 financial results and provide a corporate update during a live webcast on August 6, 2025, at 8:00 a.m. ET. The webcast can be accessed via the company’s investor page, with a replay available post-event.
07-30 20:05
Celcuity Stock Skyrockets On Breakthrough Trial Data For Heavily Pretreated Breast Cancer
Celcuity shares jump as gedatolisib shows strong efficacy in HR+/HER2- breast cancer Phase 3 trial, with FDA filing expected in late 2025.
07-28 21:42
Arvinas CEO John Houston to retire
Arvinas (NASDAQ:ARVN) announced that president and CEO John Houston plans to retire from his roles at the biotech company following the appointment of a successor. The company has initiated a search f...
07-09 19:36
